A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

Recruiting now. Registry record last updated August 3, 2026.

Who can join: Adults 65+, women only, have type 2 diabetes, BMI 27+.
What you take: semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 2.5 years; your own time in it is usually shorter.
What you get: Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 3Sponsor Emory UniversityDrug semaglutideClass GLP-1 RASites 1 USEnrollment target 20

What this study is for

Primary condition: Diabetes Mellitus, Type 2.

Full scientific study title: Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes.

Who can join

Age65 and upSexFemaleBMI27 to 40

Adults 65+, women only, have type 2 diabetes, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Postmenopausal women aged 65 years or older
Has type 2 diabetes
Body Mass Index (BMI) ≥27 kg/m² to max 40kg/m2 (inclusive)
Hemoglobin A1c \>7% within 3 months of the first visit.
Willingness and ability to comply with all study procedures, including fasting requirements for certain visits.

Key exclusion criteria

Patients with type 1 diabetes mellitus or other types of diabetes that are not T2D
eGFR \<30 ml/min in the last 3 months
Patients with a history of treatment with anti-osteoporosis agents
Documented primary or secondary osteoporosis on a DEXA scan within the last 12 months, or are on osteoporosis therapies
Documented presence of prosthesis or devices in the spine or hip

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Georgia1 site

Grady Memorial Hospital
Atlanta, Georgia
Thaer Idrees, MD, FSSCI404-251-5357thaer.idrees@emory.edu

Follow this trial

We email you if NCT07428746 changes status, adds new sites in your state, or if a similar trial opens for the same condition. No spam, opt out any time.

Timeline

Started enrolling: May 7, 2026. Expected completion: November 2028. Last updated on ClinicalTrials.gov: August 3, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.